DB17577InvestigationalProtein Based Therapies
Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.
- Mechanism
- Curator reviewed
Pharmacologically active on T-cell surface glycoprotein CD8
- Also known as
- Iab22m2c (antibody fragment against the human cd8-antigen on cd8-positive t-cells) · Imaginab
- Code names
- IAB22M2C
Resolves to
Compound
What you can answer from here — as of July 08, 2026
Which companies are running trials of Crefmirlimab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account